The lawsuit, filed by the Rosen Law Firm, focuses on Hims securities purchased between August 4, 2025, and July 29, 2026. Plaintiffs claim the company failed to disclose that it shared consumer health information with third-party advertising platforms. Furthermore, the complaint alleges Hims charged customers for prescriptions immediately after intake forms were submitted, despite marketing claims that patients would first consult with medical providers to determine appropriate treatments.

These disclosures reportedly triggered regulatory scrutiny and potential financial penalties, causing share prices to drop when the information reached the market. Investors interested in the case can contact Phillip Kim at the Rosen Law Firm to join the action. While a class has not yet been certified, those who held stock during the period may participate in potential recoveries without serving as the lead representative.